Related Experiment Video
Updated: Sep 14, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer
Dror Lifshitz1, Avi Ben-Haroush2, Dror Meirow3
1Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, Israel.; Faculty of Medical and Health Science, Tel Aviv University, Israel..
Research Question:
Do fertility preservation outcomes differ between newly diagnosed breast cancer patients stimulated with FSH and tamoxifen compared with FSH and Letrozole?
Design:
Retrospective cohort study of fertility preservation treatments in newly diagnosed breast cancer patients at two tertiary centres (2000-2022).
Results:
Patients that underwent 354 fertility preservation cycles participated in the study (n = 290): letrozole (n = 215) and tamoxifen (n = 139). Treatments with letrozole were associated with higher FSH dosages (3970 ± 2027 IU versus 2839 ± 1052 IU, P < 0.001) but were of shorter duration (9.7 versus 10.5 days, P < 0.001). The letrozole group achieved lower peak oestradiol levels (1508 ± 1242 pmol/l versus 8760 ± 5771 pmol/l, P < 0.001) and endometrial thickness (8.1 mm ± 2.4 versus 9.5 ± 2.6 mm, P < 0.001). Mean oocyte number retrieved per cycle was comparable between the groups (13.6 ± 11.7 with letrozole versus 14.7 ± 9.8 with tamoxifen, P = 0.06). In 122 patients taking letrozole and 46 patients taking tamoxifen who underwent strictly oocyte cryopreservation cycles, the mean number of cryopreserved oocytes per cycle was comparable (11 ± 8.4 versus 12.1 ± 7.9, P = 0.21). Similar results were obtained in embryo cryopreservation: letrozole (n = 71 cycles) versus tamoxifen (n = 76 cycles) (6.2 ± 7.1 versus 7.0 ± 5.3, respectively, P = 0.12). Oocyte maturation rates among strictly oocyte preservation cycles were comparable (86 ± 17% with letrozole versus 83 ± 14% with tamoxifen, P = 0.06), as were fertilization rates in embryo cryopreservation cycles (IVF: 62 ± 26% versus 63 ± 26%, P = 0.8; intracytoplasmic sperm injection: 71 ± 28% versus 76 ± 23%, P = 0.30) with letrozole and tamoxifen, respectively. Multivariate analysis, controlling for potential confounders showed no significant correlations between treatment type and the number of retrieved oocytes or maturation rates.
Conclusion:
Letrozole or tamoxifen co-administration with FSH yielded similar number of retrieved and cryopreserved oocytes and embryos, as well as similar oocyte maturation and fertilization rates.
Related Concept Videos
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Treatment Resistant Cancers
Infertility in Males
Teratogenicity

